This recent study aims to evaluate the number of skin cancers missed during teledermatology assessment. It concludes that single-lesion teledermoscopy diagnoses have high concordance with in-person evaluation and histology; however, in-person examination may reveal other suspicious lesions. The importance of a full-body skin examination should be emphasized to the referrer.
Authors of this recent study propose increasing access to multidisciplinary teams and encouraging patient advocacy groups that can guide and collaborate with researchers and decision makers to develop better treatments and care delivery models.
According to this recent study, the incidence of uveal melanoma (UM) in Australia from 1982 to 2014 peaked in the 1990s. Although treatment for primary UM has improved in the last 30 years, overall survival did not change significantly in the last 30 years.
According to this recent study, acral lentiginous melanoma( ALM) was independently associated with sentinel lymph node positivity and had relatively high positivity rates at clinical stage IB and II. This suggests that sentinel lymph node biopsy should be encouraged for all patients with clinical stage IB and II ALM.
The objective of this recent study was to explore the perceived barriers and facilitators towards mobile health apps for skin cancer screening among the Dutch general population. It concludes that developers should create a transparent identity and build trustworthy apps. Collaboration between app developers, general practitioners and dermatologists is advocated and special attention should be given to the development of low-cost, privacy-friendly, easy-to-use apps.
According to this recent study, second line therapy with PD-1 inhibitors plus BRAF±MEK inhibitors has substantial activity and manageable toxicity. This treatment can induce additional durable complete responses in patients with metastatic melanoma who have progressed on initial immunotherapy.
This study is a retrospective analysis of patients treated in the EORTC 1325/KEYNOTE-054 adjuvant pembrolizumab study. Patients with resected stage III melanoma in the original study were randomised to adjuvant pembrolizumab or placebo for a duration of one year. The study concludes that pembrolizumab treatment after crossover yielded an overall 3-year PFS rate of 32% and a 39% ORR in evaluable patients, but the efficacy (11% ORR) was lower in those rechallenged.
This recent study evaluated the CD122-preferential interleukin-2 pathway agonist bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in first-line metastatic melanoma. It concludes that BEMPEG in combination with NIVO was tolerated, with relatively low rates of grade 3 and 4 treatment-related and immune-mediated adverse events. The combination had encouraging antitumor activity in first-line metastatic melanoma.
This meta-analysis was conducted to evaluate survival outcomes and toxicities of simultaneous use of radiotherapy (RT) and immune checkpoint inhibitor (ICI) therapy in patients with melanoma brain metastasis (MBM). It concludes that concurrent administration of RT and ICI evinced favorable OS outcomes and acceptable safety profile in MBM patients.
Authors of this recent review discuss the current knowledge on oxidative stress and its signaling in melanoma, as well as the oxidative stress-related mechanisms in the acquired resistance to targeted therapies.